Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition (Q38118439)

29 August 2017

Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition (English)

1 reference

29 August 2017

1 reference

1 reference

head and neck carcinoma

1 reference

Barbara Burtness

1

1 reference

PubMed ID

23816296

29 August 2017

Julie E Bauman

series ordinal

2

1 reference

PubMed ID

23816296

29 August 2017

Thomas Galloway

series ordinal

3

1 reference

29 August 2017

1 July 2013

1 reference

Lancet Oncology Commission

29 August 2017

1 reference

29 August 2017

14

1 reference

29 August 2017

8

1 reference

29 August 2017

e302-9

1 reference

Habitual risk factors for head and neck cancer

29 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

The beverage maté: a risk factor for cancer of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

TP53 mutations and survival in squamous-cell carcinoma of the head and neck.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Prognostic significance of truncating TP53 mutations in head and neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Human papillomavirus and survival of patients with oropharyngeal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

The mutational landscape of head and neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Platinum-based chemotherapy plus cetuximab in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Cell signaling by receptor tyrosine kinases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Correlates and determinants of nuclear epidermal growth factor receptor content in an oropharyngeal cancer tissue microarray

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Dasatinib blocks cetuximab- and radiation-induced nuclear translocation of the epidermal growth factor receptor in head and neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Nuclear EGFR contributes to acquired resistance to cetuximab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Nuclear epidermal growth factor receptor interacts with transcriptional intermediary factor 2 to activate cyclin D1 gene expression triggered by the oncoprotein latent membrane protein 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Nuclear functions and subcellular trafficking mechanisms of the epidermal growth factor receptor family

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

¹¹¹In-Bn-DTPA-nimotuzumab with/without modification with nuclear translocation sequence (NLS) peptides: an Auger electron-emitting radioimmunotherapeutic agent for EGFR-positive and trastuzumab (Herceptin)-resistant breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Comparative prognostic value of epidermal growth factor quantitative protein expression compared with FISH for head and neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Targeting ErbB-1 and ErbB-4 in irradiated head and neck cancer: results of in vitro and in vivo studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Met, metastasis, motility and more

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

MET signaling pathway: a rational target for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Expression of hepatocyte growth factor and c-met protein is significantly associated with the progression of oral squamous cell carcinoma in Taiwan.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Hepatocyte growth factor inhibits anoikis by induction of activator protein 1-dependent cyclooxygenase-2. Implication in head and neck squamous cell carcinoma progression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Involvement of the hepatocyte growth factor/scatter factor receptor c-met and of Bcl-xL in the resistance of oropharyngeal cancer to ionizing radiation.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

MET Y1253D-activating point mutation and development of distant metastasis in advanced head and neck cancers.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Intratumoral c-Met expression is associated with vascular endothelial growth factor C expression, lymphangiogenesis, and lymph node metastasis in oral squamous cell carcinoma: implications for use as a prognostic marker

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Effect of c-Met Expression on Survival in Head and Neck Squamous Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Head neck squamous cell carcinoma c-Met⁺ cells display cancer stem cell properties and are responsible for cisplatin-resistance and metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

C-Met inhibitor MK-8003 radiosensitizes c-Met-expressing non-small-cell lung cancer cells with radiation-induced c-Met-expression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Epithelial to mesenchymal transition in head and neck squamous carcinoma: association of Src activation with E-cadherin down-regulation, vimentin expression, and aggressive tumor features.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Evidence for mesenchymal-like sub-populations within squamous cell carcinomas possessing chemoresistance and phenotypic plasticity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Histone deacetylase-1 and -2 expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Chemical agents that promote chromatin compaction radiosensitize tumour cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

The ERBB network: at last, cancer therapy meets systems biology.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Synthetic lethal screen of an EGFR-centered network to improve targeted therapies.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Aurora kinase inhibition overcomes cetuximab resistance in squamous cell cancer of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Nuclear localization of signal transducer and activator of transcription 3 in head and neck squamous cell carcinoma is associated with a better prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Inhibition of STAT-3 results in greater cetuximab sensitivity in head and neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Targeting Stat3 abrogates EGFR inhibitor resistance in cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Inhibition of the signal transducers and activators of transcription (STAT) 3 signalling pathway by AG490 in laryngeal carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Phosphorylation of Akt (Ser473) predicts poor clinical outcome in oropharyngeal squamous cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

mTOR expression and prognosis in elderly patients with laryngeal carcinoma: uni- and multivariate analyses.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Comment on "epidermal growth factor receptor is essential for toll-like receptor 3 signaling"

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

HIF-2alpha-mediated activation of the epidermal growth factor receptor potentiates head and neck cancer cell migration in response to hypoxia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

EGFR overexpression induces activation of telomerase via PI3K/AKT-mediated phosphorylation and transcriptional regulation through Hif1-alpha in a cellular model of oral-esophageal carcinogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck--a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

p16, Cyclin D1, and HIF-1α Predict Outcomes of Patients with Oropharyngeal Squamous Cell Carcinoma Treated with Definitive Intensity-Modulated Radiation Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970085-8

7 January 2021

10.1016/S1470-2045(13)70085-8

Identifiers

DOI

1 reference

29 August 2017

1 reference

PubMed ID

23816296